Aeras commits further USD$5 million to existing TB research agreement with Crucell
"This technology, which is based on one of the most advanced vector delivery systems for induction of cellular immunity, represents an important part of the portfolio of vaccines we are developing against tuberculosis," said Dr. Jerald C. Sadoff, President & CEO of Aeras Global TB Vaccine Foundation. "We are excited about our continued collaboration with Crucell to support the process development and manufacturing of this promising vaccine candidate."
In March 2004, Aeras and Crucell entered into a collaborative agreement for the development of a PER.C6® and AdVac®-based TB vaccine. The vaccine entered the phase I clinical trial in October 2006."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.